AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did NRX Pharmaceuticals Stock Plunge 12.79%?
Generated by AI AgentAinvest Pre-Market Radar
Friday, Jun 13, 2025 5:27 am ET1min read
NRX Pharmaceuticals' stock price plummeted by 12.79% in pre-market trading on June 13, 2025, marking a significant downturn for the biopharmaceutical company.
NRX Pharmaceuticals reported a Q1 2025 net loss of $5.5 million, a slight improvement from the $6.5 million loss in the same period last year. The company's operating losses also decreased, indicating some progress in cost management.
NRX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics based on its NMDA platform for treating central nervous system disorders. The company's innovative approach to drug development has garnered attention from analysts and investors alike.
Despite the recent stock price decline, some analysts remain optimistic about NRX Pharmaceuticals' long-term prospects. The average twelve-month price target for the stock is $28.50, with the highest target at $46. This suggests that investors believe in the company's potential for growth and success in the biopharmaceutical industry.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Regenxbio shares surge 7.99% on renewed investor confidence in strategic direction and clinical progress.
Dec.22 2025
Metallus Inc. (MTUS) plunges 6.73% as divergent analyst ratings and earnings scrutiny drive pre-market selloff.
Dec.22 2025
Oracle shares jumped 6.63% on Dec. 22 2025 on AI cloud growth forecast and strategic alliances.
Dec.22 2025
Nvidia shares surged 3.93% in pre-market Dec. 22 trading on renewed confidence in AI and data center demand.
Dec.22 2025
Personalis (NASDAQ:PSNL) surges 7.89% on renewed investor confidence driven by strategic direction and collaborations
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet